BANK VONTOBEL/CALL/ELI LILLY & CO/390/0.1/21.06.24 | Delayed Deutsche Boerse AG 16:05:02 20/05/2024 BST | ||
| 36.11 EUR | +2.03% |
|
| Current month | -4.12% | ||
| 1 month | +3.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 36.11 | +2.03% |
| 17/05/24 | 35.39 | -1.34% |
| 16/05/24 | 35.87 | -0.86% |
| 15/05/24 | 36.18 | +5.11% |
| 14/05/24 | 34.42 | +0.44% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 04:05 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6BRF |
| ISIN | DE000VU6BRF6 |
| Date issued | 17/04/2023 |
| Strike | 390 $ |
| Maturity | 21/06/2024 (32 Days) |
| Parity | 10 : 1 |
| Emission price | 4.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.08 € |
|---|---|
| Lowest since issue | 4.22 € |
| Spread | 0.02 € |
| Spread % | 0.05% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Warrants
- Warrant
